Navigation Links
New therapy enlists immune system to boost cure rate in a childhood cancer
Date:5/27/2009

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

John M. Maris, M.D., chief of Oncology at The Children's Hospital of Philadelphia, co-authored the phase 3 clinical trial, which was led by Alice Yu, M.D., Ph.D., of the University of California, San Diego. Maris chairs the committee supervising the trial for the Children's Oncology Group, a cooperative organization that pools resources from leading medical centers to study and devise new treatments for pediatric cancers.

Neuroblastoma, a cancer of the peripheral nervous system, usually appears as a solid tumor in the chest or abdomen. Neuroblastoma accounts for 7 percent of all childhood cancers, but due to its often aggressive nature, causes 15 percent of all childhood cancer deaths.

Yu will present the neuroblastoma study results on June 2 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. In advance of the meeting, ASCO published the findings online on May 14.

Maris explained that immunotherapy for cancer involves triggering the body's immune system to attack cancer cells. Monoclonal antibodies are molecules customized to target particular cancers, while cytokines are naturally occurring signaling proteins that regulate the body's immune responses.

In the current study, Children's Oncology Group researchers studied 226 children with high-risk neuroblastoma. Half received the immunotherapy, while half received standard therapy (chemotherapy and stem cell transplantation). The patients who received the immunotherapy were 20 percent more likely than those in the standard therapy group to live disease-free two years after treatment. "This 20 percent improvement in preventing relapse led to a greater cure ratethe first substantial increase in cure rate for neuroblastoma for more than a decade," said Maris.

The researchers halted the trial earlier than expected after early results showed the benefits of immunotherapy. "This experimental immunotherapy is poised to become part of the new standard of care for children with the aggressive form of neuroblastoma," said Maris.

Maris added that the supply of the antibodies and cytokines used in the trial was limited, and that pediatric oncologists were seeking biotechnology companies to move the biological agents into commercial production to make the treatment readily available to children with neuroblastoma.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Worlds First Animatronic Animal Therapy Program Set to Open
2. What You Need to Know in Your 40s to Have a Healthy Menopause -- Without Hormone Replacement Therapy
3. Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise
4. CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
5. Pills Plus Psychotherapy Can Beat Insomnia
6. Study Shows NeuroStar TMS Therapy(R) Improved Key Elements of Cognition in Patients with Major Depressive Disorder
7. MEDai Helps Medicare Part D Sponsors Adhere to CMS Medication Therapy Management Initiative
8. Theravive.com Expands Values Counseling and Therapy Into Michigan, Florida, and Washington State
9. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
10. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
11. FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... FCPX LUT Vintage Volume 2 for ... look. FCPX LUT Vintage Volume 2 contains 60 different color-grade presets, giving editors multiple ... vignettes and blurs to single out subjects, plus much more. FCPX LUT Vintage Volume ...
(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus ... cancer among men in the U.S. and the third most common cause of cancer related ... one man in seven will be diagnosed with prostate cancer during his lifetime. Those ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality ... weekends so that visits to the dentist fit into their patients’ busy lifestyles. ...
(Date:6/23/2017)... ... 23, 2017 , ... The Rhode Island Quality Institute (RIQI) ... and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care ... and Dashboards provide near real-time data about patients admitted to and/or discharged from ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:5/30/2017)... 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global ... announced that it will be presenting at the 7th annual LD ... Erez Raphael , CEO, of DarioHealth will be giving the ... held on June 6th & 7th, 2017 at the Luxe Sunset ... / micro-cap space. About LD ...
Breaking Medicine Technology: